Recent Updates
Recently added Catalysts
CGTX Positive Sentiment

Results from COG0201: a Randomized, Placebo-controlled, Double-blind, International, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Adults with Mild-to-Moderate Alzheimer’s Disease: Focus on Pre-specified Lower p-tau217 Subgroup

Friday, November 1, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The COG0201 study evaluated CT1812's safety and efficacy in adults with mild-to-moderate Alzheimer's disease. This randomized, placebo-controlled, double-blind Phase 2 trial focused on a pre-specified subgroup with lower p-tau217 levels. Results were presented at the Clinical Trials on Alzheimer's Disease conference in Madrid, highlighting the potential of CT1812.
Price reaction · baseline $0.4721 (2024-10-31 close) · hit pre-market · 3 other CGTX headline(s) in the window, move may be shared
day 0 close
-0.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • CT1812 shows promise in treating mild-to-moderate Alzheimer's disease.
  • The study is part of a rigorous international clinical trial.
  • Focus on a specific subgroup may enhance treatment efficacy.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress

Full Press Release Details

Woodward M, Vijverberg EGB, Di Caro V, et al. Results from COG0201: a Randomized, Placebo-controlled, Double-blind, International, Phase 2 Study to Evaluate the Safety and Efficacy of CT1812 in Adults with Mild-to-Moderate Alzheimer’s Disease: Focus on Pre-specified Lower p-tau217 Subgroup . Slides presented at Clinical Trials on Alzheimer’s Disease (CTAD) 2024; Madrid, Spain

Frequently Asked Questions

What is the COG0201 study about?

The COG0201 study evaluates the safety and efficacy of CT1812 in Alzheimer's patients.

What type of study was COG0201?

COG0201 is a randomized, placebo-controlled, double-blind Phase 2 study.

Where were the results of the study presented?

Results were presented at the Clinical Trials on Alzheimer's Disease conference in Madrid.

What subgroup did the study focus on?

The study focused on a pre-specified subgroup with lower p-tau217 levels.

ShareAdd on Google
Tags: CGTX Viatris Investor Conferences Healthcare CT1812 Alzheimer's disease Phase 2 study p-tau217 clinical trials
Last updated: Nov 1, 2024

Biotech snapshot

Cash runway
$34M liquidity · $1M/mo burn
~33 mo
Minimal dilution risk
Lead asset
OxytocinPhase 2
Oxidative Stress →

Catalyst track record

+35%
best trade around CGTX's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for CGTX.

See every catalyst's timing & PoA →